Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

ion, or $0.11 per share, compared with net income of $7.9 million, or $0.14 per share, for the same prior year period. The net loss for the nine months ended September 30, 2008 includes a non-operating charge of $3.1 million that reflects an other than temporary decline in value of the Company's equity investments.

As of September 30, 2008, the Company had approximately $88.7 million in current and non-current unrestricted cash, cash equivalents and marketable securities.

2008 Financial Guidance

The Company has revised its royalty revenue upward from previous guidance for 2008 to range from $33 million to $36 million. The Company recognizes royalty revenue on a cash basis when it is received. The Company has reduced its anticipated milestone receipts relating to the sale of products to Mayne Pharma to $1.8 million for 2008. Research and development expenses for 2008 have been revised downward and are expected to total approximately $33 million to $35 million. The growth over 2007 continues to be influenced by increasing costs related to clinical trial programs such as MP-470, ongoing pre-clinical product development efforts and investments in the discovery, pre-clinical, manufacturing, regulatory and clinical development operations of the Company. The Company expects to record a charge during 2008 of approximately $5.2 million for acquired in-process research & development resulting from a milestone payment to the former Montigen stockholders. This payment is contingent on the filing of an Investigational New Drug (IND) application (and upon the IND going into effect) with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology. Selling, general and administrative expenses are expected to be lower from previous guidance and are forecasted to be approximately $12 million for 2008. Included in 2008 total operating expenses are non-cash stock-based compensation expenses of approximately $3 million. Based on th
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , RESEARCH TRIANGLE PARK, N.C., July 22 ... it has completed its acquisition of Stiefel Laboratories, Inc. GSK has ... $2.9 billion. GSK also assumed $0.4 billion of net debt. ... additional cash payments of up to $0.3 billion depending on the future ...
... DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 ... serving the Middle East, Africa, Turkey & Caspian regions, today ... supply agreement with Axcan Pharma for Pylera (R) , an ... pylori , a bacterium now recognized as being the main ...
... , CHICAGO, July 22 ... annual meeting today indicates that monitoring cardiac transplant patients with ... help clinicians to monitor cyclosporine-induced toxicity and adjust doses of ... , , In a scientific ...
Cached Biology Technology:GlaxoSmithKline Completes Acquisition of Stiefel 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 3Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... the familiar semi-aquatic bugs gliding across the lake at the ... walk on water. This was not always the case. ... unique arrangement of the legs, with the mid-legs greatly elongated. ... Evolutionary Biology have discovered the gene behind this evolutionary change. ...
... human brain distinctly separates the handling of images of ... image type in a different area of the brain. ... visual information in this manner to optimize processing the ... people who have been blind since birth the brain ...
... Sandbar, dusky and tiger sharks are among dozens of ... East Coast. Little is known about many of the species, ... scientists and fishery resource managers to monitor shark populations and ... Northeast Fisheries Science Center (NEFSC) lab in Narragansett, R.I., recently ...
Cached Biology News:Brain innately separates living and non-living objects for processing 2Scientists conduct shark survey off US East Coast 2Scientists conduct shark survey off US East Coast 3
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... Pfx DNA Polymerase is ideal for ... downstream applications such as cloning and ... by a proprietary enzyme preparation containing ... with proofreading (3'Cut Site5' exonuclease) activity. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... offers precision beveling of micropipette ... The unique abrasive plate drive ... greater control of the beveling ... very rapidly and produces consistent ...
Biology Products: